Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Hans-Joachim SchmollD G Haller

Abstract

To report the final efficacy findings and biomarker analysis from the NO16968 trial comparing bolus fluorouracil/folinic acid (FU/FA) with capecitabine plus oxaliplatin (XELOX) in resected stage III colon cancer. After curative resection, patients were randomly assigned to receive XELOX, as oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks, or bolus FU/FA, as the Mayo Clinic or Roswell Park regimens, for 6 months. The primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS). The intention-to-treat population comprised 1,886 patients (XELOX, n = 944; FU/FA, n = 942). Seven-year DFS rates were 63% and 56% in the XELOX and FU/FA groups, respectively (hazard ratio [HR], 0.80; 95% CI, 0.69 to 0.93; P = .004). Seven-year OS rates were 73% and 67% in the XELOX and FU/FA groups, respectively (HR, 0.83; 95% CI, 0.70 to 0.99; P = .04). A total of 68% and 77% of patients who experienced relapse or a new colorectal cancer in the XELOX and FU/FA groups, respectively, received drug treatment for metastatic disease. Four hundred ninety-eight patients consented to the biomarker analysis: 242 in the XELOX group and 256 in the FU/FA group. Low t...Continue Reading

References

Feb 8, 1990·The New England Journal of Medicine·C G MoertelJ H Glick
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N WolmarkN J Petrelli
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J O'ConnellH S Wieand
Jun 4, 2004·The New England Journal of Medicine·Thierry AndréUNKNOWN Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Jul 1, 2005·The New England Journal of Medicine·Chris TwelvesWerner Scheithauer
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel G HallerRobert J Mayer
Dec 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans-Joachim SchmollDaniel G Haller
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Philip KueblerNorman Wolmark
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thierry AndréAimery de Gramont
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J SargentUNKNOWN ACCENT Group
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thierry AndréAimery de Gramont
Jan 25, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D SargentUNKNOWN Adjuvant Colon Cancer End-points (ACCENT) Group
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel G HallerHans-Joachim Schmoll
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Greg YothersNorman Wolmark
Sep 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollA Cervantes
Apr 11, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Claus-Henning KöhneFrank Biertz

❮ Previous
Next ❯

Citations

Jan 23, 2016·Expert Opinion on Pharmacotherapy·Kenichi Sugihara, Yasushi Tsuji
May 10, 2016·Expert Opinion on Pharmacotherapy·J J M Kwakman, C J A Punt
Mar 20, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jenny DrottCarina Berterö
Jun 16, 2016·Future Oncology·Jonathan M Loree, Winson Y Cheung
Jan 12, 2016·Clinical Colorectal Cancer·Alexandra Lapeyre-ProstUNKNOWN Groupe Coopérateur Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the UNICANC
Sep 13, 2016·International Journal of Cancer. Journal International Du Cancer·F N van ErningV E P P Lemmens
Oct 4, 2016·Drug Discovery Today·Harshali PatilRupinder K Kanwar
Apr 18, 2015·BMC Cancer·Silvina GrassoMiguel Saceda
Oct 11, 2016·Expert Review of Gastroenterology & Hepatology·Erin B MothPrunella Blinman
Jun 15, 2015·Clinical Colorectal Cancer·Amy Soni, Edward Chu
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars A PåhlmanBengt Glimelius
Nov 20, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·C MazzaO Bouche
Apr 12, 2017·Journal of Gastrointestinal Cancer·Jorge Hernando-CuberoJaume Capdevila
Jan 20, 2017·International Journal of Clinical Oncology·Kazuhito MinamiUNKNOWN Kyushu Study Group of Clinical Cancer (KSCC)
Jul 18, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Aaron ShaSharlene Gill
Feb 27, 2018·Expert Review of Anticancer Therapy·Monica TangMatthew Burge
Feb 14, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SobreroA Cervantes
Jan 3, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H E DanielsenD J Kerr
Apr 6, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thierry AndréUNKNOWN for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER
Sep 13, 2016·Annals of Surgery·Meredith C MasonNader N Massarweh
Mar 23, 2018·JAMA Oncology·Andrea CercekMartin R Weiser
Jun 7, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R-D HofheinzUNKNOWN German Rectal Cancer Study Group
May 26, 2018·Minerva chirurgica·Iris H Wei, Julio Garcia-Aguilar
Mar 14, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-François DelattreMagali Svrcek
Jun 25, 2016·The Cancer Journal·Carling UrsemAlan Venook
Jun 17, 2020·Expert Review of Clinical Immunology·Maryam Balibegloo, Nima Rezaei
Dec 19, 2017·Oncology Letters·Magdalena SzaryńskaZbigniew Kmieć
Oct 2, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans-Joachim SchmollKarin Haustermans
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Nadine Jackson McClearyRodrigo Dienstmann
Apr 19, 2019·BMJ Case Reports·Ana PissarraAna Neto Plácido
May 18, 2019·The Journal of International Medical Research·Serkan DegirmenciogluArzu Yaren
Dec 28, 2016·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Xinru YouJun Wu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved